|Bid||0.0000 x 1200|
|Ask||0.0000 x 1000|
|Day's Range||1.5700 - 1.6100|
|52 Week Range||1.0900 - 3.7800|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 8, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.17|
Keryx's (KERX) loss in the first quarter of 2018 was narrower than expected while sales beat estimates. The company remains encouraged by the performance of its lead drug Auryxia.
Endocyte (ECYT) incurs narrower-than-expected loss in the first quarter of 2018. The company finalized a phase III VISION study design for its pipeline candidate 177Lu-PSMA-617 in the quarter.
Catalyst reported in-line loss in Q1. The company resubmitted a new drug application for its lead candidate Firdapse and expects FDA to accept the NDA in Q2.
The Cambridge, Massachusetts-based company said it had a loss of 29 cents per share. The company's shares closed at $1.79. A year ago, they were trading at $1.36. _____ This story was generated by Automated ...
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2018, and reviewed recent business progress.
In this commentary, I will examine Catabasis Pharmaceuticals Inc’s (NASDAQ:CATB) latest earnings update (31 December 2017) and compare these figures against its performance over the past couple of years, asRead More...
NEW YORK, May 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Church ...
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, will report first quarter 2018 financial results before the NASDAQ Global Market open on Thursday, May 10, 2018.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Facebook, Inc. (NASDAQ: FB ) stock traded higher by ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on April 25) Eleven Biotherapeutics Inc (NASDAQ: EBIO ) Integra Lifesciences ...
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today reported new positive magnetic resonance efficacy results showing slowed disease progression in boys with Duchenne muscular dystrophy (DMD) in the MoveDMD trial through 48 weeks of edasalonexent treatment. Both magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) were performed in the Phase 2 MoveDMD trial and open-label extension. Statistically significant improvement in the rate of change in lower leg composite MRI T2 at 12, 24, 36 and 48 weeks on oral 100 mg/kg of edasalonexent treatment were observed compared to the off-treatment control period (p
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that it will present new magnetic resonance imaging data from the open-label extension MoveDMD trial of edasalonexent for the treatment of Duchenne muscular dystrophy at the American Academy of Neurology 70th Annual Meeting to be held April 21 – 27, 2018, in Los Angeles, CA, at the Los Angeles Convention Center....
Alnylam (ALNY) announced encouraging results from phase I and phase I/II open-label extension studies of givosiran, which is being evaluated for the treatment of acute hepatic porphyrias.
Shares of Alkermes (ALKS) rose when the FDA accepted for review the new drug application for its depression candidate ALKS 5461 two weeks after it had issued a Refusal to File letter.
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced a restructuring of the organization to focus resources on the Company’s late-stage lead program, edasalonexent for the treatment of Duchenne muscular dystrophy .
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies. The candidate is progressing well in the Janssen sponsored studies.
Bellicum (BLCM) agrees to make amendments to the protocols relating to clinical studies evaluating its T Cell Therapy, BPX-501.
Epizyme (EPZM) publishes tazemetostat phase I clinical data in The Lancet Oncology. The study demonstrated favorable safety findings and anti-tumor activity.